Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07075705 | Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy | recruiting | N/A | 138 | Roswell Park Cancer InstituteOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07335796 | A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer | active not recruiting | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07593079 |
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer |
| not yet recruiting |
| Phase 2 |
| 20 |
| Washington University School of MedicineOTHER |
| 1 |
| Sep 11, 2026 |
| clinicaltrials |
| NCT07815197 | Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer(PERSEUS) | not yet recruiting | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | active not recruiting | Phase 1 | 152 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03315754 | Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. | completed | Phase 2 | 50 | Steba Biotech S.A.OTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05448547 | Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer(GrandP/SPCG19) | recruiting | Phase 3 | 980 | Sven LöffelerOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT05762536 | Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC(DAROTAXEL) | recruiting | Phase 2 | 245 | Erasmus Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05766371 | Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | recruiting | Phase 2 | 48 | University of California, San FranciscoOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05946213 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | recruiting | Phase 3 | 1,209 | NRG OncologyOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT06040125 | Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial | recruiting | N/A | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06100705 | Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC | recruiting | Phase 2 | 26 | Yale UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06886321 | Prostate Irreversible Electroporation Study | recruiting | N/A | 10 | Chinese University of Hong KongOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07491198 | Effect Of Trendelenburg Position And Pneumoperitoneum On Optic Nerve Sheath Diameter In Robot-Assisted Prostatectomy(ONSD-RALP) | recruiting | — | 50 | Ege UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01480154 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03317392 | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | active not recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04396808 | Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer | active not recruiting | N/A | 805 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04592237 | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05804318 | Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer(ARTIA-Prostate) | recruiting | N/A | 132 | Varian, a Siemens Healthineers CompanyINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06607783 | PRostate Cancer Enhanced Diagnosis by Calibration Technology(PREDICT) | recruiting | — | 66 | Gold Standard PhantomsINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07226713 | Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors(POSTPONE) | recruiting | Phase 2 | 32 | Medical College of WisconsinOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07468708 | The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer | recruiting | Early Phase 1 | 10 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07529717 | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer(CRIUS-1) | recruiting | Phase 1 / Phase 2 | 42 | AstraZenecaINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07576335 | Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy(ROBOPREP) | recruiting | Phase 2 | 64 | Surgical Outcomes Research Centre (SOuRCe)NETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07808528 | Advanced Diffusion Magnetic reSonance Prostate Imaging for Reducing Extraneous Biopsies (ASPIRE) - Calibration Component (Multi-centre Scanner Calibration) and Validation Component (Multi-centre Validation)(ASPIRE MS) | not yet recruiting | N/A | 660 | University College, LondonOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07810660 | RE-irradiation for Isolated FOCal Recurrence of Prostate Cancer With Ultrahypofracted SBRT(RE-FOCUS) | not yet recruiting | — | 60 | European Institute of OncologyOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT03035500 | Long-Term Follow-Up in Patients With Prostate Cancer After Surgery | active not recruiting | N/A | 2,500 | City of Hope Medical CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03354416 | Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer | recruiting | — | 10,000 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03976843 | Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | active not recruiting | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY) | active not recruiting | Phase 2 | 47 | Rana McKay, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05762198 | Comparing Water Vapour Thermal Therapy (Rezūm) and TURP | completed | N/A | 108 | Chinese University of Hong KongOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05800665 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Genentech, Inc.INDUSTRY | 7 | Sep 8, 2026 | clinicaltrials |
| NCT06051162 | HPI Effect in Robotic Urological Surgery on AKI | completed | N/A | 124 | Ewha Womans University Mokdong HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06067295 | Longitudinal Advanced Prostate Cancer Cohort (LAPCC) | recruiting | — | 300 | University of Southern CaliforniaOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06690970 | Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients | recruiting | — | 500 | Tianjin Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07224009 | Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) | recruiting | Phase 2 | 60 | University of ArkansasOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07735377 | A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer | recruiting | Phase 1 | 118 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07806539 | Hemodynamic Monitoring-Guided Goal-Directed Fluid Therapy in Robotic Radical Prostatectomy | completed | — | 48 | Antalya Training and Research HospitalOTHER_GOV | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807293 | Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE(SALVAGE) | not yet recruiting | Phase 2 | 62 | University of British ColumbiaOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04597359 | To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Sep 4, 2026 | clinicaltrials |
| NCT04821622 | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | active not recruiting | Phase 3 | 599 | PfizerINDUSTRY | 27 | Sep 4, 2026 | clinicaltrials |
| NCT06384222 | Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone | active not recruiting | Phase 2 | 32 | Ivan de Kouchkovsky, MDOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06555796 | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | active not recruiting | Phase 1 | 50 | AmgenINDUSTRY | 2 | Sep 4, 2026 | clinicaltrials |
| NCT07542379 | The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer | recruiting | Early Phase 1 | 13 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07567846 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 260 | Genentech, Inc.INDUSTRY | 3 | Sep 4, 2026 | clinicaltrials |
| NCT07661641 | A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors | recruiting | Phase 1 | 115 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07751133 | Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer(ENHANCE) | recruiting | Phase 3 | 1,500 | University College, LondonOTHER | 1 | Sep 4, 2026 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials